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Key points:  
• An instrument – the Side Effect Patient ASsessment Tool (SE-PAST) - was developed to 
enable lay persons to assess suspected side effects 
• The primary purpose of the SE-PAST was to empower patients in their consultations with 
health professionals 
• The SE-PAST was validated amongst people who had experienced a suspected side 
effect(s) from a medicine 
• The majority of participants found the SE-PAST easy to use and a potentially useful 
healthcare tool 
•  Further work is required to confirm its reliability/validity and to determine its ability to 
improve consultations with health professionals 
 
Word count: 3328 
Disclosure: This study was funded by the Medway School of Pharmacy. Some preliminary results 
from this work were presented at the EuroDURG meeting held in Glasgow, UK (November 2017). The 









Purpose: Research into causality assessment tools enabling patients to assess suspected adverse 
drug reactions (ADRs) is limited. Supporting patients with tools could improve their confidence in 
discussions with health professionals and encourage reporting of suspected ADRs to regulators. This 
study describes development and preliminary validation of an instrument: Side Effect Patient 
ASsessment Tool (SE-PAST). 
Methods: 
SE-PAST was developed from survey and interview data involving patients experiencing suspected 
ADRs. It included 10 statements enabling causality assessment, covering timing, additional 
information sources and experiences, with four options: yes/no/don’t know/not applicable. Scoring 
and weighting resulted in four categories of causal association: highly probable, probable, possible, 
unlikely. 
Validation involved obtaining feedback from 31 individuals experiencing an ADR. Further validation 
involved on-line distribution through patient support groups and comparison of reported symptoms 
to known ADRs. 
Results: 
Validators found SE-PAST easy to read (31), to understand (27) and complete (29). 294 respondents 
completed SE-PAST on-line, with 98% completing eight or more causality assessment statements. 
Symptoms were categorised as: highly probable (46; 16%), probable (80; 62%), possible (44; 15%) 
and unlikely (21; 7%). A total of 221 respondents identified one suspected medicine, with 95% of 
these reporting at least one symptom known to be an ADR. 
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Of 227 providing feedback, 139 (61%) found SE-PAST useful, 160 (71%) felt motivated to discuss 
their experience with a health professional and 136 (60%) were encouraged to report to the 
regulator. 
Conclusion: 
SE-PAST was easily completed and understood by people experiencing suspected ADRs and could be 
















Adverse drug reactions (ADRs) are common and can severely impact on peoples’ daily lives.1  ADRs 
are all types of undesired effects caused by medicine - these unintended effects are sometimes 
referred to as side effects (SE).2 While ADRs are always harmful, SE can include beneficial as well as 
harmful effects. The terms ADRs and SE are frequently used interchangeably in patient information, 
and we do so in this paper. While patient adherence to medicines is essential for positive health 
outcomes, consistent patient adherence can be difficult to achieve.3,4 ADRs have been identified as 
one of the most important barriers to patients’ adherence.3,5 Yet studies suggest that, for some 
people, suspected harmful effects from medicines which they raise with health professionals are 
dismissed.6,7 Person-centredness in healthcare is increasingly advocated8,9, which requires 
exploration and acknowledgement of individuals’ personal experiences. Facilitating individuals to 
describe their experiences of ADRs could enable useful discussions with health professionals about 
treatments and provide medicine regulators with valuable data to improve public health. Health 
professionals also need to recognise individuals’ ability to identify ADRs for themselves, in order to 
appreciate the impact these may have on daily life and on future adherence to medicines. Research 
has found that suitable eHealth tools can assist patients, encouraging them to play a larger role in 
shared decision making and might increase focus on and may lead to improvements in patient-
physician relationships.10,11 A recent systematic review showed that patients found the eHealth tools 
they used for self-management and monitoring helpful in improving communication with HCPs, 
however none of the tools identified focused specifically on ADRs.12 
Several studies have illustrated the mechanisms used by lay people to identify ADRs, and proposed a 
framework for understanding these.13,14,15 People use five cognitive domains to help identify ADRs, 
based on the Self-Regulation model of health behaviour: identity; timeline; cause; consequences and 
control.16 This framework provides insight into patient experience and can highlight the impact 
which ADRs have on their lives.14,17,18 People use their previous personal health experiences or 
6 
 
knowledge of others’ experiences14 and timing of symptoms in relation to medicines use to identify 
ADRs.19,20 The majority employ temporal associations to link symptoms to medicines and display 
knowledge and accuracy in identifying experiences as ADRs. Some use additional information from a 
range of sources, such as patient information leaflets (PILs), supplied with all dispensed and 
purchased medicines in the EU, to confirm suspected ADRs.21 These fundamental processes for 
assessing causality parallel those employed by healthcare professionals20 and suggest that a 
standardised method could be effectively used by lay people to carry out a coherent causality 
assessment.  
Causality assessment is an essential function of pharmacovigilance centres where standardised, 
highly structured methods are used. Instruments available for assessing causality are however 
designed for use by professionals working in these centres and were not created for use by general 
clinicians or patients.22,23 Few patient-focused instruments exist. One instrument for patient self-
assessment of ADRs was developed and tested in Thailand24 where access to sources of medicines 
information, such as PILs, is very limited.25  This novel instrument, which incorporated a previously 
validated checklist of potential SE from medicines26 displayed reliable psychometric properties in 
preliminary testing and received positive evaluations from patients, but has undergone no further 
testing. A patient-reported adverse drug event (ADE) questionnaire, also incorporating checklists, 
was developed and validated in the Netherlands27, designed for use in clinical trials and post-
marketing studies, rather than in clinical practice. An assessment tool designed to help patients 
decide whether symptoms they experience are linked to their medicines, the RxISK Report, is 
available on the Canadian RxISK drug safety website.28 This tool requires comprehensive information 
including drug start/stop dates, drug dosage/frequency and patients must also supply their email 
details to receive the RxISK score and report. Generic assessment tools could aid patients in deciding 
whether to report experiences they suspect to be ADRs to health professionals. They may also 
increase confidence to initiate such discussions, increasing the patient-centredness of consultations. 
In addition, it may encourage more reporting to national regulatory agencies, which have 
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increasingly advocated and facilitated direct patient reporting.29  We therefore set out to develop an 
instrument for these purposes, derived from the experiences of patients in identifying suspected 
ADRs for themselves, for use in the UK setting, where there is widespread availability of medicine 
information sources, such as PILs.  
Objectives  
The objectives of this study are to develop an instrument to enable laypersons to assess suspected 
SE, validate the instrument amongst people experiencing a suspected SE, further validate the 
instrument in a broader population, and determine the perceived usefulness of the assessment 
instrument. 
Methods 
Instrument development  
The instrument developed was based on the Self-Regulation Model of Health Behaviours 16,30,31 and 
the Thai patient causality assessment tool.24  The Side Effect Patient ASsessment Tool (SE-PAST) was 
primarily informed by the findings of two studies involving patients in England who had experienced 
an ADR: a survey exploring information sources used to find out about ADRs32 and in-depth 
interviews with people who had recently experienced an ADR, exploring in detail the cognitive 
processes used to identify and confirm ADRs.33  The term ‘side effect(s)’ was selected for use in the 
instrument as inclusive wording that would be more familiar to respondents than ADR and 
encourage reporting of mild/minor effects..  
Respondents were instructed in the development and validation phases – verbally and through the 
instrument’s instructions - to focus one side effect/symptom or one group of side effects/symptoms 
when answering the questions.  
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The instrument, Side Effect Patient ASsessment Tool (SE-PAST) (See Appendix 1), comprised:  
Section A – This section was composed of nine questions in total asking about the following: 
Background information, describing suspected ADR experience (question 1), open/closed questions 
covering timing (question 2), impact on daily life (question 3; four-point scale: none, mild, moderate, 
severe), medicines being used (question 4), suspected causative medicine (question 5) and allergies 
and medical conditions (question 6). Basic demographic questions - gender, age group and 
education level - were included to enable an assessment of the population using the instrument 
(questions 7-9). 
Section B – Self-assessment tool with ten statements, with four possible responses (‘Yes’, ‘No’, 
‘Don’t know’, ‘Not applicable’), with a scoring system to calculate a score, which could be 
categorised using a probability key. Scores were assigned to one of four degrees of causal 
association: highly probable, probable, possible, unlikely. Respondents were advised to contact a 
relevant health professional and consider reporting their experience through the Yellow Card 
Scheme, for any experience categorised as possibly, probably or highly probably a SE from a 
medicine. The format of the tool was similar to the Naranjo algorithm, due to its simplicity. The 
weighting of the score for each statement was also based on the Naranjo algorithm.34  
Validation processes 
In phase one, face validity was assessed by three pharmacist members of the research team, then by 
members of a public engagement group. All were asked to provide feedback on instrument content 
and format. Following this, minor format amendments were made and in phase two, face and 
content validity was assessed with adult English residents who had experienced a suspected ADR. 
These consisted of (i) interviewees from the study which informed the instrument 
development33and (ii) members of the public known to the research team who had experienced an 
ADR. All completed a paper copy of the instrument, then provided feedback on its’ structure, clarity, 
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and usability, their general opinion and any suggestions for improvement. Participants could provide 
feedback by returning a form by post, or through telephone interview, both covering the same 
questions. No personal identifiable information was recorded. Vouchers with a monetary value of 
£10 were offered to participants as an incentive to participate.  
An electronic version of the instrument was then developed for phase three - online distribution 
using Qualtrics®. This assigned scores automatically to each response and calculated the score, 
avoiding the need for respondents to do so. This version included a pre-screening component with 
appropriate questions which sought to ensure respondents had experienced a suspected SE. The 
first question in SE-PAST then asks respondents to describe their SE, including relevant information. 
To assess the potential value of the instrument, participants completing the SE-PAST were invited to 
respond to additional questions covering its usefulness and its potential for encouraging them to 
report their suspected SE to the UK regulatory authority or talk to a health professional about it. All 
responses were anonymous. Analysis of the online data enabled the external validity of the 
instrument to be assessed.   
Patient support groups/organisations with a record of encouraging patient engagement and 
supporting health self-management were approached via email to post a recruitment statement 
with a link to the instrument on their website. The link remained open for five months (April 2016-




Figure 1: Flow diagram of study methodology 
 Aim Participants 
Instrument 
development 
To develop an instrument to enable lay 
persons to assess suspected side effects 




To assess face validity of the instrument Pharmacists in 
research team (n=3) 




To validate the instrument amongst 
people experiencing a suspected side 
effect(s) 
 












PPI=PIPS (Public Involvement in Pharmacy Studies) 
 
Data analysis 
Data from the online survey were downloaded into SPSS for Windows V23 for analysis. Simple 
descriptive statistics were used to report patient characteristics. Medicines suspected as having 
caused reported suspected ADRs were classified into major therapeutic areas according to the 
British National Formulary (BNF version 72). To assess external validity, symptoms reported were 
assessed by review of the Summary of Product Characteristics available on-line for the reported 
suspect medicine (www.emc.org) and, if not found, in published case reports. Missing statements in 
the causality assessment tool were assigned a value of 0 (equivalent to don’t know/does not apply) 
to enable calculation of probability levels for all respondents.  Chi-squared test was used to assess 
the relationship between completion of all statements and probability level, utilising a statistical 
significance level of p≤0.05. Associations between causality and gender, age group or educational 
level were also investigated. Free-text descriptions of suspected SE experiences were transferred 







There were 31 individuals who took part in the initial face and content validation of the SE-PAST, 11 
were interviewees from the previous study and 20 were members of the public known to the 
research team. A majority were female (21; 68%) 14 were aged 50 or below, 11 aged 51 to 70 and six 
were over 70. Just over half were university educated (16; 52%). The time taken to complete the 
entire instrument ranged from five to forty-five minutes, but 24 (77%) completed it in less than 15 
minutes. All 31 judged the instrument easy to read, 87% (27) easy to understand, 97% thought it was 
clearly laid out and only one thought it was too long. Following this only changes to the initial 
instructions were made, to improve clarity. 
Online survey - Response rates and demographic details 
In total 15 patient support groups/organisations were approached via email and seven agreed to 
post a recruitment statement with a link to the instrument on their website. The SE-PAST instrument 
was accessed online a total of 761 times during the five month period, with 563 people (74%) 
consenting to participate. Of these, 312 subsequently accessed the instrument, however 18 then 
indicated in response to the first question that they had experienced no suspected SE. Of the 
remaining 294 respondents, the majority were female (208), 185 were aged over 60 and 168 were 












Side effect experiences 
Details of their suspected SE experience was provided by 294 respondents as free-text comments. 
These included 255 (87%) who described physical symptoms, 46 (16%) describing psychological 
symptoms and 74 (25%) describing social impacts (Table 2).  
Table 2 Extracts from free-text comments illustrating impacts and methods of identification  
 
Respondent details Suspected medicine Description 
Male, age 61-70, 
university-educated, 




symptoms with social 
impact (P138) 
 
simvastatin Taking simvastatin, I began to experience pains in 
the low back and hip which affected me during the 
night. I would go to bed with no pain and then 
around 2 or 3 o clock in the morning I would be 
woken by the pains in the hips so that I was unable 
to get back to sleep again.  I discussed this with the 
doctor who didn't believe the statin was the cause.  
But in the end I stopped taking the drug.  After 
about 9 months the pains had finally disappeared. 
At that point the doctor persuaded me to re-start 
the simvastatin, I agreed, and within 2 weeks the 
nocturnal hip pains had returned. 
Female, age 41-50, topiramate Slower cognitive processing, which manifests itself 
Characteristic  Frequency (%) 
Gender Female 208(71.5) 
(n=291) Male 83(28.5) 
Age (years) Below 40 27(9.2) 
(n=292) 41-50 31(10.6) 
 51-60 49(16.8) 
 61-70 105(36.0) 
 71-80 68 (23.3) 
 Over 80 12(4.1) 
Education level School 62(21.4) 
(n=290) Further education 60(20.7) 
 University 168(57.9) 






(n=294) One 85(28.9) 
 2-4 123(41.8) 
 5-9 60(20.4) 




on 2-4 medicines, 
causality level 
probable, mild impact, 
physical symptoms 
with social impact 
(P147) 
 
particularly as sometimes groping for words or 
having difficulty forming/speaking words. This is 
worse when speaking a foreign language. I also 
sometimes find that it is harder for me to begin 
concentrating on something, like reading or writing 
(once I am concentrating, and into the flow of the 
work, the effect is less noticeable). 
Female, age 71-80, left 
school at 16/younger, 
on 2-4 medicines, 
causality level 
probable, moderate 
impact (P179) physical 
& psychological 
symptoms with social 
impact 
sertraline A constant feeling of weariness of mental capacity 
and lack of enthusiasm, somehow encouraging 
thoughts of a depressive nature.  Irritable 
digestion, difficulty in concentrating. 
Male, age 61-70, 





symptoms with social 
impact (P196) 
 
bendroflumethiazide I was prescribed bendroflumethiazide to reduce 
swelling in my ankles. I developed gout, specifically 
in my knees and elbows. At one point I was only 
able to walk with the aid of a crutch. The pains in 
my arms and elbows was less severe and could be 
relieved by massage. I put up with the discomfort 
for some time not realising that it was linked with 
taking a diuretic.  A pharmacist friend made me 
aware of the links between diuretics and gout.  I 
stopped taking the bendroflumethiazide.  The gout 
symptoms slowly went away and have now 
completely disappeared.  
Female, age 61-70, 
further education, on 





cinacalcit [Cinacalcit] definitely, because I became violently 
sick whenever I took it and stopped when I 
stopped taking them. According to my doctor it is 
already a known side effect. 
 
Most (292) gave information about when the experience occurred; almost half (136; 50%) 
experienced the suspected in the past six months, while the remaining respondents indicated 
experiences more than six months previously. All but one rated the severity of their experience; 115 






Most respondents (283) listed their medicines at the time of the suspected SE; 85 (30%) reported 
using one medicine, while 198 (70%) reported using more than one (Table 1). Despite the majority of 
respondents using multiple medicines, only 24 (8%) were unsure what drug had caused the 
suspected SE, and 49 (17%) reported combined/multiple medicines either within or across 
therapeutic areas, whereas 221 (75%) respondents identified a single medicine they thought had 
caused their symptom(s). The proportion who cited multiple possible causative medicines increased 
with the number of medicines reported as being used (Figure 2). 
Figure 2 Number of potentially causative medicines cited in relation to number being used 
 
The therapeutic areas were determined for the causative medicines cited by all 221 who cited a 
single medicine plus a further 14 who cited two medicines in the same therapeutic area.  The most 
frequently cited therapeutic groups of medicines reported to cause SE were those acting on the 
cardiovascular system (74; 32%), central nervous system (66; 28%), and endocrine system (34; 15%). 
Females identified medicines acting on the central nervous system most frequently (59/167; 35%), 
while males most frequently identified medicines acting on the cardiovascular system (37/66; 56%). 




















No of medicines used
no causative drug reported one causative drug reported multiple causative drugs reported
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60 years (57/143; 40%) whereas centrally-acting medicines were more common in younger 
respondents (43/91 (47%).  
All ten questions in the causality assessment section were completed by 184 respondents (63%), 80 
(27%) completed nine and 25 (9%) completed eight, thus 98% completed at least eight statements 
(Table 3). Three respondents did not complete any of this section. Responses to the causality 
statements were supported by free-text comments (Table 2).  
For the 184 respondents with fully completed responses, 38 (21%) experiences were categorised as 
highly probable, 119 (65%) probable, 18 (10%) possible and nine (5%) unlikely to be an ADR. 
Imputing scores of 0 (equating to a response of either do not know/does not apply) for missing 
responses allows estimation of causal association for 291 respondents. Based on all those 
completing any causality statements, 46 (16%) experiences were categorised as highly probable, 180 
(62%) probable 44 (15%) possible and 21 (7%) unlikely to be an ADR. Hence completion of all 
questions increased the likelihood of a higher score (p<0.001), and therefore a higher level of 
probability. There were no differences in the category of causality dependent on gender, age group 
or educational level. 
External validity  
External validation, assessed by comparison of reported symptoms to known ADRs as documented 
in the current Summary of Product Characteristics found that of the 221 who identified one 
potentially causative medicine, the majority (194; 95%) reported at least one known ADR. For 16 
respondents (7%) none of the symptoms were listed, and a further two respondents described 
symptoms indicating potential lack of efficacy. For the symptoms described by the remaining nine 




Perceived value of the instrument 
Following completion of the SE-PAST, 227 respondents agreed to answer additional questions on the 
instrument’s value. Of these, 139 (61%) found the SE-PAST useful, 136 (60%) were encouraged to 
report their suspected ADR to the relevant agency and 160 (71%) felt motivated to discuss their 
suspected ADR with a health professional.  
 
Discussion 
The SE-PAST was developed to enable patients to assess suspected SE, from medicines, its  
primary purpose being to increase empowerment for patients in their consultations with health 
professionals.  A suitable assessment tool for patients to use prior to their consultations could 
facilitate a productive partnership between patients and their HCPs. This is increasingly important, 
given the trend towards patient-centred consultations and their involvement in decision-making 
around treatments, including medicines. Opportunities to use such a tool need to be created, for 
example making it available on practice websites, in leaflets designed to help patients prepare for 
medicine reviews, or in more general practice leaflets, perhaps promoted on video screens in 
waiting areas. If patients decide to report their experience to regulatory authorities, an assessment 
tool specifically developed for patient use could also enhance the quality of such reports. In this 
case, providing a link to the assessment tool from the Yellow Card website would be the most 
practical way to enable its use. 
Main findings 
The SE-PAST instrument was found to be easy to use, not onerous in terms of time and seen as 
potentially valuable by a majority of respondents who had experienced a suspected SE from a 
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medicine. The background information section of the instrument was designed to facilitate recall of 
the event and record this, while the causality assessment tool facilitated a simple calculation of a 
probability level for the association with a medicine. Taken together, these details have the potential 
to enable those who experience a symptom they consider to be related to a medicine to assess for 
themselves the likelihood that it could be a SE. This could lead to the provision of relevant 
information either to a health professional which might lead to treatment changes to reduce the risk 
of future ADRs, and improve adherence, or to a regulatory agency, adding to the data used to 
protect public health from the harms of medicines. 
Comparison to literature 
Although other instruments designed to facilitate self-assessment of symptom causality exist, they 
do have limitations. The use of symptom checklists, used in both the Dutch and Thai instruments, 
while facilitating expression of experiences, can result in over-reporting of adverse events. They can 
create confusion in respondents unable to distinguish between events potentially related/unrelated 
to medicines.  The Thai instrument24 was tested to ensure that it was clear, consistent and easy for 
lay persons to use and facilitated them in calculating a probability level. However it required the 
recall of a large amount of detailed information about their experience, use of information sources 
and potentially causative medicines, which, given the dispensing practices and lack of medicine 
information in Thailand, led to recall difficulties. No weightings were given to the individual 
statements used in the causality assessment tool, in contrast to standard methods, such as the 
Naranjo method, on which it was based. This instrument was validated by comparison to 
information contained within medical records and probability levels were strongly correlated with 
respondents’ perceived certainty of their experience being an ADR. Completion of the instrument 
did not increase respondents’ degree of certainty in the association of the medicine with the 
suspected SE, but over 80% considered it helped them to assess their symptom. 
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The developers of the Dutch instrument concluded that its reliability for facilitating patients in 
clinical trials to report ADRs was limited and suggested that it required improvement for this 
purpose.27  Both this and the Thai instrument did show satisfactory reliability using the test-re-test 
method. External validity of the Dutch instrument assessed by comparison to the Summary of 
Product Characteristics found that 73% of symptoms were known ADRs23, lower than was found for 
the SE-PAST (95%). 
Since the purpose of the instrument was primarily to empower patients in consultations with health 
professionals, ease of use and appropriate level of content are probably the most relevant 
characteristics. Both the initial and online validation of the SE-PAST indicated good face and content 
validity, as well as potential usefulness.  The SE-PAST is much shorter than the existing instruments 
as it does not contain a symptom checklist and when used online it also avoids the need for 
respondents to calculate probability levels themselves. There is of course potential for an instrument 
such as this to adversely affect adherence, if it confirms a suspicion that a medicine could be related 
to an unwanted symptom. Therefore advice is given to users to discuss their experience with a 
health professional, if the probability level is possible or higher. Future research could further 
develop the online instrument so it can (a) be printed by respondents and taken to their HCP 
consultations  and (b) include a link to the MHRA Yellow Card Scheme website/be submitted to the 
MHRA.  In addition the SE-PAST could be assessed to determine if it could aid patients who are 
currently experiencing SE. 
Limitations 
We were not able to evaluate the individual reported experiences of those completing the SE-PAST 
to confirm the likely causality of the event using information from medical records. While this is a 
desirable method of assessing validity, it is not essential for the instrument to be of value in 
empowering patients to discuss suspected ADRs with health professionals or to trigger a report to a 
relevant regulatory agency.  Reliability testing using test-re-testing was not undertaken. Those 
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involved in initial validation were all known to the team, either directly or as interviewees in a 
previous study. The sample for the online validation were of necessity self-selected, the majority 
were university-educated and most were female. This may limit the generalisability of the results. 
Females are known to have higher use of patient support groups and to use groups differently from 
men, but they also use more medicines and have higher rates of ADRs.35 A large number of the 
people who accessed the online instrument failed to complete it. The reasons for this cannot be 
ascertained and could be many and varied. In addition, not all those who completed the SE-PAST 
responded to evaluation questions and may have been less likely to consider it useful.  
Relevance to practice 
A causality assessment instrument specifically developed for lay use may help to facilitate effective 
discussions between patients and healthcare professionals about suspected ADRs, empowering 
patients and improving patient-centredness of consultations. While such an instrument could also 
prompt the discontinuation of medicines, it should be acknowledged that patients frequently 
discontinue medicines of their own volition, either to test their suspicions of SE themselves or to 
otherwise evaluate its effects.33,35   In addition, the possibility exists that an experience categorised 
as ‘unlikely’ may deter patients from discussing it with a health professional, although this study 
suggests that few experiences are so categorised.  The instrument could also contribute to 
increasing the number of, and enhancing the quality of, reports to regulatory authorities which do 
not require causation to be proven prior to reporting. They can then perform further causality tests 
and signal generation to find confirmed ADRs. Incorporation of self-assessment questions such as 
those used in SE-PAST into direct patient ADR reporting could provide both lay person and 




The SE-PAST is a useful instrument which enables lay persons to self-assess causality of suspected 
ADRs from medicines. It could assist their decisions about whether to discuss these experiences with 
health professionals or report them to regulatory authorities. It is easy to use but further work is 
required to confirm its reliability and validity and to determine its ability to lead to improved 




Study approval was obtained from the Medway School of Pharmacy Research Ethics Committee (REF 
0116/2). Comprehensive information describing the purpose of the study was provided, and the 
online survey potential participants were required to access this information prior to completing the 
instrument. Written consent was obtained for interviewees. 
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